Life Sciences and Industry Magazine

European Biotechnology Spring Edition 2016 | Volume 15 | 20 €

ISSN 2364-2351 | A 60711 | InterviewEC Bioeconomy Director John Bell on the vital role biotech has to play in the future circular economy

InterviewEC Bioeconomy Director John Bell on the vitalrole biotech has to play in the future circular economy

Stocks take a diveDark times for IPOs

Clinical trialsWhat probably went wrong in the recent French trial disaster

DiabetesNew strategies for fighting the dangerous lifestyle disease

Circular EconomyEC legislates the end of the wasteful throw-away society

BioprocessingNovel techniques and services for personalised healthcare

FREE EXCERPT

MORE PREDICTIVE

MORE HUMAN

Setting the standard in genetically engineered

& precision research mouse models

APRIL SYMPOSIA

Advanced preclinical mouse models for Immunology, Oncology & Infectious DiseaseNorway, Sweden, France, The Netherlands, & Germany

EU: +45 70 23 04 05INFO@TACONIC.COM

TACONIC.COM LEARN MORE: TACONIC.COM/EU-SPRING

4 European Biotechnology | Spring Edition | Vol. 15 | 2016ContEntS

InsIght EuropE

6 IMSHealthprovidesfirst-everdataanalysisonbiologics-biosimilarcompetitioninEurope

8 Failed French Phase I trial on FAAH blocker casts involved CRo in a poor light

10 EU’shigh-levelexpertgrouppraisesFP7;EMAexpands conflictofinterestpolicytomanagementboard;NewIMIcalltargetschallengeswithBigDataand Ebola

12 EuropeanCommissionagaindelayspolitical decision on novel genetic breedingmethods;Heardin Brussels:Circulareconomy– whytalkskeepongoingaroundincircles

Economy

20 IPConferenceinLifeSciences: Exploringpatentabilityand commercialisationstrategiesforBigDatainnovations

22 IP Flash; Boostformicrobiomecompanies

23 Update on clinical trials

28 EMANews

29 Analystcommentary

30 Euro Biotech Stocks

32 Start-upstory:Immunethep, Cantanhede,Portugal

Surviving the turmoil on capital markets

covEr story

Equitymarketshavebeenundersiegeformonths,withmacroeconomicef-fectsandsector-specificissuesbrakingtradingonbothsidesoftheAtlantic.ButtherearegoodreasonstoremaincautiouslyoptimisticdespitethefallinIPOs.Cashisstillavailable,andprom-isingnewtreatmentsarecomingthickandfast.Sothere’shopethateveniffirmshavetowaittogopublic,they’llnowbebetterabletocrossthefund-ingValleyofDeaththathasclaimedsomanyyoungbiotechsinthepast.

IMPRIntEuropeanBiotechnology(ISSN2364-2351)ispublishedquarterlyby:BIOCOMAG,Lützowstr.33–36,D-10785Berlin,Germany,Tel.:+49-30-264921-0,Fax:+49-30-264921-11, Email:service@eurobiotechnews.eu,Internet:www.eurobiotechnews.eu;Publisher:AndreasMietzsch,EditorialTeam:ThomasGabrielczyk(EditorinChief),DerrickWilliams(Co-editor),UtaMommert,Dr.MartinLaqua,JulieColthorpe,Dr.BerndKaltwaßer;Advertising:OliverSchnell,+49-30-2649-2145,ChristianBöhm,+49-30-2649-2149,AndreasMacht,+49-30-2649-2154; Distribution:MarcusLaschke,+49-30-2649-2148;GraphicDesign:MichaelaReblin;Productioneditor:BenjaminRöbig;Printedat:Königsdruck,Berlin;EuropeanBiotechnologyLifeSciences& IndustryMagazineisonlyregularlyavailablethroughsubscriptionatBIOCOMAG.Annualsubscriptionfees:€80.00,Students€40.00(subjecttoproofofenrolment).PricesincludeVAT,postage&packaging.OrderedsubscriptionscanbecancelledwithintwoweeksdirectlyatBIOCOMAG.Thesubscriptionisinitiallyvalidforoneyear.Subscriptionswillberenewedautomaticallyforonemoreyear,respectively,unlesstheyarecancelledatleastsixweeksbeforethedateofexpiry.FailuresofdeliverywhichBIOCOMAGisnotresponsiblefordonotentitlethesubscribertodeliveryorreimbursementofpre-paidfees.SeatofcourtisBerlin,Germany.Asregardscontents:individuallynamedarticlesarepublishedwithinthesoleresponsibilityoftheirrespectiveauthors.Allmate-rialpublishedisprotectedbycopyright.Noarticleorpartthereofmaybereproducedinanywayorprocessed,copiedandproliferatedbyelectronicmeanswithoutthepriorwrittenconsentofthepublisher.Supplement:SwissBiotechAssociation,CoverPhoto:©magann/fotolia.com.®BIOCOMisaregisteredtrademarkofBIOCOMAG,Berlin,Germany.

14

rEgIonal nEws

38 northern Europe: Sweden,Denmark,Finland, andNorway

40 WesternEurope: France,Belgium,TheNetherlands andtheUK 44 Central Europe: Austria,GermanyandSwitzerland

46 Southern Europe: Italy,Spain,Portugal,Malta,Croatiaand Slovenia

48 Eastern Europe: Hungary,Poland,Latvia, LithuaniaandSlovakia

scIEncE & tEchnology

56 Interview:JohnBell,Directorof Bioeconomy,DGResearch& Innovation,EuropeanCommission

70 Europeansleadlargest-everDNA forensicsprogramme

72 Theglovesareoff:Battleon theCRISPRfront

sErvIcE

73 Newsfrompartnerassociations: SBA,BIODeutschland,DIA,EBN,EDMA

79 Biopeople

80 Events81 Companyindex82 Encore

Pict

ure:

mag

ann/

foto

lia.c

om

FREE EXCERPT

5European Biotechnology | Spring Edition | Vol. 15 | 2016 ContEntS

EdItorIal

the Big PictureCrashing oil prices, finite resources, mountains of waste and growing threats like diabetes are challenging stock exchanges, the environment, healthcare systems and job markets. UK researchers expect the projected spread of diabetes – from currently 382 million people worldwide to 592 million by 2035 – to almost double treatment costs. And that’s not all. They also say the lifestyle disease will massively decrease productivity and employment opportunities. Our editor Martin Laqua looks at strategies in the pipeline for treating the lifestyle dis-ease (p. 34). Cheap oil and global competition for access to scarce raw materials are also encouraging volatility on stock mar-kets, and that's having a major effect on biotech performance, as Bernd Kaltwaßer reports on p. 14. And those scarce resources are having an impact on another vital discussion. Last December, the European Com-mission laid the groundwork on a strategy for ending the throw-away so-ciety and switching to a circular econ-omy. But experts are concerned that the plan will fall short (see p. 50). With so many global problems to be solved, Europeans will have to im-prove cooperation worldwide instead of fostering isolationalistic trends such as closing EU borders to refugees or thinking of a possible BREXIT. Only collaboration can help, and biotech can be part of a solution.

ThomasGabrielczyk

Editor-in-Chief

cIrcular Economy

Can Europe stop the flood of waste?Even as natural resources start running low,theamountofwasteweproduceispeaking.EUpolicymakersareworkingonwaystoescapefromtheunsustain-ableparadigmofathrow-awaysociety.Andoneofthebiggestopenquestionsishowmuchbiotechwillbeneededtomaketheirvisionareality.

dIabEtEs

The latest approachesUnhealthylifestylesaremakingdiabetesoneofthegreatestplaguesofthenewcentury.Althoughpreventionisprefer-abletotreatment,there’snoquestionthatthemarketforinnovativenewapproachesinthesectorisexpandingfordevelopers,andalotofmoneyisatstake. EuroBiotEch provides an over-viewofthelatestideasandproductsfrombiotechnology.

34

SPECIAL

Bioprocessing

50

61 Intro: Mastering more patient-centric bioprocessing – allogenic versus autologous CAR-T cell therapies

64 Advertorial: Next biomanufacturing hub

66 Analytical technologies: highly auto-mated protein characterisation

Pict

ures

: Mat

ic Št

ojs,

foto

lia.c

om (r

ight

), No

vo N

ordi

sk (l

eft),

IDT B

iolo

gika

(bot

tom

)FREE EXCERPT

12 European Biotechnology | Spring Edition | Vol. 15 | 2016

Pict

ure:

EBN

InSIght EuropE

Heard in BrusselsGoing round in circles

Brussels I am too depressed to write about the UK playing silly buggers with the EU and the negative impact on science, so let’s look at some-thing positive for Eu-rope instead – the de-velopment of circular economy opportuni-ties for biotechnolo-gy. Let’s start by ex-plaining what the circular economy is, before you say ‘eh?’ and read something else. Its aim is to en-sure that the value of products, mate-rials and resources is maintained in the economy for as long as possible, and the generation of waste minimised.

It essentially looks at production, consumption and waste as a bigger picture, something the EU is genu-inely able to do, with the aim to ben-efit citizens and the ecosystem of Eu-rope in the long term. We can expect a combined set of actions that include regulation and economic develop-ment incentives and this is genuinely an opportunity for biotechnology to find new applications and create glo-bal economic opportunities. Because Europe follows a long term approach, it might be faster than many other re-gions in the world, which are more re-active than proactive, in creating sci-entific and business capabilities.

European biotechnology is already working towards economic return from circular economy actions, look at the Bio-Based Industries (BBI) Joint Un-dertaking, a public private partner-ship leveraging €2.7 billion of private investment and €975 million EU funds to target sustainable biomass, biore-fineries and market development. This

matches the prin-ciples of the circu-lar economy action plan published at the end of 2015 which has the intention to change production processes, consump-tion, waste manage-ment and turning waste into a resource – all areas where bio-technology can work its magic.

Most areas of bio-technology can con-tribute; food pro-duc t ion, energy,

environmental monitoring, industrial processes etc etc, there’s room for inno-vation and economic return across the board. A quick look at the BBI work-plan for 2016 highlights the commer-cial opportunities for biotech perfect-ly, with topics including extraction of organic material from waste water for feedstock, novel fermentation of bio-compounds, advanced biomaterials for packaging, recovering and re-using enzymes in industrial processes … the list goes on, read it yourself you lazy beggars.

The circular economy makes sense for Europe – the world is demonstrat-ing on a daily basis how economies and society suffer when the environ-ment is degraded. There will certain-ly be plenty of moaning about Brus-sels stopping you throwing your fridge in the pond or making you dry your hair with a straight banana. However, if we take the 20-year, “isn’t the water clean”, view rather than the 5-minute, “it’s my human right to leave the fridge door open”, view – we will hopefully find that Europe is still habitable and we have thriving industries that will help make that happen.

Claire skentelBery Secretary General of the Euro-pean Biotechnology Network

GMO invasion agri-BioteCH novel biotech breeding methods are challenging the existing reg-ulations on gMos. While genetically en-gineered crops usually contain snippets of DnA from foreign organisms, novel tech-niques such as gene editing are able to design products that do not carry foreign genes. In fact, crops made by techniques, which enzymatically introduce targeted DnA cuts instead of using non-targeted radiation for the same purpose, can’t be distinguished from breeds created by tra-ditional random mutagenesis.

Experts from the uS Department of Agriculture (uSDA) have already estab-lished a case-by-case regulatory pathway for such breeds. As long as the product does not differ from conventionally-bred crops, the regulatory authority exempts them from gMo review, providing a much cheaper pathway to market ap-proval. In gMo-hostile Europe, legisla-tors have so far delayed a political solu-tion to the pressing problem even though a scientific analysis from 2012 said there was no difference between plants created by random and targeted mutagenesis. the European Commission’s plans to close the legal loophole by providing a novel gMo definition, have been shifted twice since last June. In mid-December, the Commis-sion announced it will present its solution at the end of March.

however, Finland, germany, Ireland, Spain, Sweden and the uK have already made their decisions. According to Shawna Mcgregor, spokesmen at the uS company Cibus Inc, these national authorities decided that its herbicide-tolerant “oDM canola” is definitely no gMo. “the competent authorities concluded that the rapeseed varieties in question did not come under the scope of Directive 2001/18,” confirmed McGregor. However, field trials, which Cibus had started in the uK in 2012 and in Sweden, have been put on hold. European plant researchers at EpSo recently stressed that research, industry and farmers urgently need legal clarification concerning the application of novel breeding technologies.

FREE EXCERPT

14 European Biotechnology | Spring Edition | Vol. 15 | 2016RuBRik

Pict

ures

: xxx

15European Biotechnology | Spring Edition | Vol. 15 | 2016 CoVER StoRySo

urce

: Cre

dit S

uiss

e Firs

t Bos

ton

(200

5–3/

2015

), BI

OCO

M A

G, D

ata k

indl

y pro

vide

d by

DZ

Bank

AG

(201

5–20

16 Y

TD);

Pict

ure:

rolffi

mag

es/f

otol

ia.c

om (l

eft)

IPOs: The times they are a-changin’industry sentiment Early January saw a few indicators that stock markets might deliver

some solid biotech results in 2016, even if it isn’t destined to be a hallmark year for the industry.

But then, in the weeks that followed, the situation began to deteriorate. Now it looks like Euro-

pean biotech companies might have to start coming to terms with a closing IPO window.

Rowe Price, told the Wall Street Journal. “it’s very tough.”

there have been several early warn-ing signs that the path to going public is growing increasingly rocky. the over-all number of iPos in the uS has fallen, while more and more companies have pulled the plug on plans to take the step. Citing adverse market conditions, the first bio tech companies have decided against pursuing a listing at Euronext or AiM as well in the second half of 2015. January of 2016 was the first month without a sin-gle iPo in the uS in more than five …

›› Read the full story in the printed issue.

Equity markets overall have been under siege for many months. Macro economic effects like dwindling oil prices, imploding

Chinese stock quotes and closer scruti-ny of Russia’s economic powerbase have been braking trading on both sides of the Atlantic. And sector -specific concerns like drug-pricing debates and looming patent expiries haven’t helped ameliorate the sit-uation for biotech firms.

Will 2016 see sector carnage?

At first glance the outlook looks pretty grim. Between 1 January and mid-Feb-ruary, the Nasdaq Biotechnology index

(NBi) lost about 25% of its value. the first month of 2016 was also the third-worst monthly performance in the meas-ure’s history. Comprising some 190 bio-tech stocks traded on the uS-based technology stock exchange, the index lost every inch of ground it had gained in 2015. it’s starting to look as if the bio-tech sector’s three-year deluge of public market debuts, with dozens of compa-nies raising billions of dollars in funding, is now rapidly grinding to a halt. And not just newcomers are seeing falls in value. “Even for the highest-quality companies, there is less demand than there was a few months ago for iPos,” Ziad Bakri, a healthcare analyst at mutual fund firm T.

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 3/2015 2015 2016 YTDEnergy29%

telecom32%

Energy32%

Biotech10%

it60%

Cons Disc26%

Biotech22%

Biotech38%

Biotech74%

Biotech33%

Biotech7%

Cons Disc9%

telecom9%

Biotech18%

Energy22%

Material20%

Cons Stap–18%

Materials45%

industrials24%

utilities15%

Financials26%

Cons Disc41%

utilities24%

Healthcare6%

Healthcare5%

utilities8%

utilities13%

Cons Disc17%

utilities16%

Healthcare–24%

Cons Disc39%

Materials20%

Cons Stap11%

Cons Disc22%

Healthcare39%

Healthcare23%

Cons Disc4%

it4%

Cons Stap2%

Healthcare5%

utilities17%

it16%

utilities–32%

S&P 50023%

Energy18%

Healthcare10%

Healthcare15%

industrials38%

it18%

telecom0%

Cons Stap4%

industrial–1%

Financials4%

Financials16%

Cons Stap12%

telecom–34%

industrials17%

S&P 50013%

Cons Disc4%

S&P 50013%

Financials33%

Financials13%

Cons Stap0%

Biotech4%

Energy–3%

S&P 5003%

Materials16%

industrials10%

Cons Disc–35%

Healthcare17%

telecom12%

Energy3%

it13%

S&P 50030%

Cons Stap13%

S&P 5000%

S&P 500–1%

Materials–3%

Materials2%

S&P 50014%

telecom8%

Energy–36%

Financials15%

Financials11%

it1%

telecom12%

it26%

S&P 50011%

Materials0%

telecom–2%

S&P 500–3%

Cons Stap1%

Const Stap12%

Healthcare5%

S&P 500–38%

Energy11%

Cons Stap11%

telecom1%

industrials12%

Materials23%

Cons Disc8%

it0%

Financial–4%

Cons Disc–4%

it0%

industrials11%

S&P 5004%

industrials–42%

Cons Stap11%

it9%

S&P 5000%

Materials12%

Cons Stap23%

industrials8%

industrials–2%

industrial–5%

it–4%

industrials0%

it8%

Biotech–3%

it–44%

utilities7%

Biotech2%

industrials–3%

Cons Stap8%

Energy22%

Materials5%

Financials–3%

utilities–9%

Healthcare–6%

Cons Disc–7%

Healthcare6%

Cons Disc–14%

Materials–47%

telecom3%

utilities1%

Materials–12%

Energy2%

utilities9%

telecom–2%

Energy–4%

Materials–11%

Financial–9%

telecom–9%

Biotech–3%

Financials–21%

Financials–57%

Biotech–7%

Healthcare1%

Financials–18%

utilities–3%

telecom6%

Energy–10%

utilities–7%

Energy–24%

Biotech–11%

Biotech vs. major industrial index’s stock price performance using S&P sector indices

FREE EXCERPT

34 European Biotechnology | Spring Edition | Vol. 15 | 2016DiaBEtES

Pict

ure:

Nov

o No

rdisk

Taking the fight to a looming epidemicDiabetes With the advance of obesity and related metabolic disorders, diabetes has become a

global threat. The good news is that thanks to better access to more and better treatment options,

mortality and morbidity linked to the illness are slowing. But that's just a first step. Diabetics now

also want advances in managing the disease. Products from improved versions of insulin to pain-

and stress-free delivery methods have a chance to grab a share of a market worth billions. And in

the background, research groups are working on concepts for actually curing the condition.

›› Read the full story in the printed issue.

FREE EXCERPT

50 European Biotechnology | Spring Edition | Vol. 15 | 2016BioEconomy

Can Europe stop the stream of waste?CirCular EConomy For decades now, Europeans have dreamed of creating a low-waste society

powered by an economy that copies cycles and principles found in nature. In December, the Eu-

ropean Commission laid the foundation stone for establishing a ‘circular economy’, which aims at

protecting the world’s finite resources by – among other measures – repairing products instead of

throwing them away. At the moment, the strategy is focused on waste prevention. But will that be

enough to meet challenges like global warming, marine debris and shortages of raw materials?

›› Read the full story in the printed issue.

Pict

ure:

Mat

ic Št

ojs/

foto

lia.c

om

FREE EXCERPT

81European Biotechnology | Spring Edition | Vol. 15 | 2016 Company IndEx

3B pharmaceuticals GmbH (GER) . . . . . . . . . . . . 44abbVie Inc. (USa) . . . . . . . . . . . . . . . . . . . . 23, 29abivax aB (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18ablynx BV (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . 25abzena plc (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 41aCE BioSciences a/S (dK) . . . . . . . . . . . . . . . . . 28aclaris Therapeutics (USa) . . . . . . . . . . . . . . . . . 18adaptimmune Ltd. (UK) . . . . . . . . . . . . . . . . . . . 29Affimed GmbH (GER) . . . . . . . . . . . . . . . . . . 44, 79albumedix (dK) . . . . . . . . . . . . . . . . . . . . . . . . . 38almirall S. a. (ES) . . . . . . . . . . . . . . . . . . . . . . . . 46alphabet (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . 20aLpLa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40angle plc (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . 40apeiron Biologics (aT) . . . . . . . . . . . . . . . . . . . . 45apogenix aG (GER) . . . . . . . . . . . . . . . . . . . . . . 19apple (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20arGEn-x B.V. (nL) . . . . . . . . . . . . . . . . . . . . . . . 23aristi Biotech BV . . . . . . . . . . . . . . . . . . . . . . . . 41asia pte Ltd (SG) . . . . . . . . . . . . . . . . . . . . . . . . . 47aSSoBIoTEC (IT) . . . . . . . . . . . . . . . . . . . . . . . . 46astraZeneca aB (SE/UK) . . . . . . . . . . 23, 24, 28,41auria (FI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39avantium Life Sciences BV (nL) . . . . . . . . . . . . . 40axxam Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . 46B.T.m. Savjetovanje d.o.o. (HR) . . . . . . . . . . . . . 47BaSF (GER) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45Bavarian nordic a/S (dK) . . . . . . . . . . . . . . . . . . 39Bayer aG (GER) . . . . . . . . . . . . . . . . . . . . . . 28, 45BC platforms (CH) . . . . . . . . . . . . . . . . . . . . . . . 39Bellerophon Therapeutics (USa) . . . . . . . . . . . . . 18Bial-portela & Ca Sa (pT) . . . . . . . . . . . . . . . . . . . 8Bio products Laboratory (UK) . . . . . . . . . . . . . . . 28Bio-on S.p.a. (IT) . . . . . . . . . . . . . . . . . . . . . . . . 47Biocartis Sa (CH) . . . . . . . . . . . . . . . . . . . . . . . . 41BIoCom aG (GER) . . . . . . . . . . . . . . . . 18, 57, 65Biodesix Inc. (USa) . . . . . . . . . . . . . . . . . . . . . . . 40Bioglobe GmbH (GER) . . . . . . . . . . . . . . . . . 70, 71Biomarin Europe Ltd. (UK) . . . . . . . . . . . . . . . . . 28Biomedica 2016 (GER) . . . . . . . . . . . . . . . . . . . . . 9Bionor pharma aSa (n) . . . . . . . . . . . . . . . . . . . 24Biontis GmbH (GER) . . . . . . . . . . . . . . . . . . . . . . 70Biophytis SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . 18Biotrial (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Boehmert & Boehmert (GER) . . . . . . . . . . . . 17, 72Boehringer Ingelheim (GER) . . . . . . . . . . 24, 36, 37Brain aG (GER) . . . . . . . . . . . . . . . . . . . . . . . 19, 45Bristol-myers Squibb (USa) . . . . . . . . . . . . . 24, 28Cambridge Innovation Capital (UK) . . . . . . . . . . 40Cassiopea Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . 29Celgene Europe Ltd. (UK) . . . . . . . . . . . . . . . . . . 24ChemChina . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45CmS Hasche Sigle (GER) . . . . . . . . . . . . . . . . . . 22Coca-Cola (USa) . . . . . . . . . . . . . . . . . . . . . 40, 54Crispr Therapeutics (CH) . . . . . . . . . . . . . . . . . . . 45Cytos Biotechnology aG (CH). . . . . . . . . . . . . . . 18danone (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40designeRx (USa) . . . . . . . . . . . . . . . . . . . . . . . . 28dIa Europe (CH) . . . . . . . . . . . . . . . . . . . . . . .Cp4Easyfairs Switzerland GmbH (GER) . . . . . . . . . . . 53Editas medicine (USa) . . . . . . . . . . . . . . . . . . . . 19Elanix Therapeutics (CH) . . . . . . . . . . . . . . . . . . . 18Eli Lilly & Co Ltd (USa) . . . . . . . . . . . . . 35, 36, 37Eli Lilly nederland . . . . . . . . . . . . . . . . . . . . . . . 28Eligo Bioscience (F) . . . . . . . . . . . . . . . . . . . . . . 22Enterome (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22Epistem Ltd (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 79Eppendorf aG/Bioprocess Center Europe (GER) . 60Eridania Sadam S.p.a. (IT) . . . . . . . . . . . . . . . . . 47

Erydel Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . 46EuropaBio/European Biotech Week (B) . . . . . . . . 13European Biotechnology network (B) . . . . . . . . . 21Evaxion Biotech (dK) . . . . . . . . . . . . . . . . . . . . . 39Evgen pharma (UK) . . . . . . . . . . . . . . . . . . . . . . . 18FIT Biotech oyi plc (FI) . . . . . . . . . . . . . . . . . . . . 18Frost & Sullivan (UK) . . . . . . . . . . . . . . . . . . . . . 94FUJIFILm diosynth Biotechnologies (USa) . . . . . 67Galapagos nV (B) . . . . . . . . . . . . . . . . . . 23, 24, 29Geneuro S.a. (CH) . . . . . . . . . . . . . . . . . . . . . . . 23Genmab a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . 29Genomics plc (UK) . . . . . . . . . . . . . . . . . . . . . . . 79genoway S. a. (F) . . . . . . . . . . . . . . . . . . . . . . . . 41GF Biochemicals (IT/nL) . . . . . . . . . . . . . . . . . . . 46Gilead Ltd. (USa) . . . . . . . . . . . . . . . . . . 23, 25 29GlaxoSmithKline (UK) . . . . . . . . . . . . . . . . . 20, 41Glycomar (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . 38HealthCap (SE) . . . . . . . . . . . . . . . . . . . . . . . . . . 39High-Tech Gründerfonds management (GER) . . . 55HTG molecular diagnostics . . . . . . . . . . . . . . . . 18IBm Corp. (USa) . . . . . . . . . . . . . . . . . . . . . . . . 20Illumina Inc. (USa) . . . . . . . . . . . . . . . . . . . . . . . 94Immunethep Sa (pT) . . . . . . . . . . . . . . . . . . . . . . 32Immunocore Ltd. (UK) . . . . . . . . . . . . . . . . . . . . 23Immunovia aB (SE) . . . . . . . . . . . . . . . . . . . . . . . 18Impasara Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . 28Imperial Innovations Group plc (UK) . . . . . . . . . 40Inivata Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 40Innovate UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38Innovation norway . . . . . . . . . . . . . . . . . . . . . . . 38Inotek pharmaceuticals (USa) . . . . . . . . . . . . . . . 18Invivoscribe Technologies (USa) . . . . . . . . . . . . . 25Ipsen (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44Jaguar animal Health (USa) . . . . . . . . . . . . . . . . 18Janssen Biotech Inc. (USa) . . . . . . . . . . . . 8, 22, 29Johnson & Johnson (USa) . . . . . . . . . . . . 37, 40, 41Karcinolys S.a.S. (F) . . . . . . . . . . . . . . . 28Kempharm (USa) . . . . . . . . . . . . . . . . . . . . . . . . 18KLm (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39Kuros Biosciences (CH) . . . . . . . . . . . . . . . . . . . 79Kuros Biosurgery aG (CH) . . . . . . . . . . . . . . . . . 18Laboratorios Farmaceuticos Rovi S.a. (ES) . . . . . 29Larix aS (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 39LEo pharma a/S (dK) . . . . . . . . . . . . . . . . . . . . . 24Life Science austria LISa (aT) . . . . . . . . . . . . . . . 33Life Science Baltics 2016 (LT) . . . . . . . . . . . . 42, 43Lufthansa aG (GER) . . . . . . . . . . . . . . . . . . . . . . 39Lysogene SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . 28m+W Central Europe GmbH (GER) . . . . . . . . . . 69maaT pharma (F) . . . . . . . . . . . . . . . . . . . . . . . . 22maikowski & ninnemann (GER) . . . . . . . . . . 26, 27mcKinsey & Co. (GER) . . . . . . . . . . . . . . . . . . . . 51medimmune Ltd (UK) . . . . . . . . . . . . . . . . . . . . . 23medivir aB (SE) . . . . . . . . . . . . . . . . . . . . . . . . . . 39merck & Co. (USa) . . . . . . . . . . . . . . . . . 35, 36, 37merck KGaa (GER) . . . . . . . . . . . . . . . . . 25, 37, 41merck Sharp & dohme Ltd (USa) . . . . . . . . . . . . 28microa aS (n) . . . . . . . . . . . . . . . . . . . . . . . . . . 38micropharma . . . . . . . . . . . . . . . . . . . . . . . . . . . 22miltenyi Biotech GmbH (GER) . . . . . . . . . . . . . . 28mitim Srl. (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 38mitsui Global Investment (Jp) . . . . . . . . . . . . . . . 40mLm medical Labs GmbH (GER) . . . . . . . . . . . . . 7mologen aG (GER) . . . . . . . . . . . . . . . . . . . . . . . 24monsanto (USa) . . . . . . . . . . . . . . . . . . . . . . . . . 45morphoSys aG (GER) . . . . . . . . . . . . . . . . . . . . . 28motif Bio plc (UK) . . . . . . . . . . . . . . . . . . . . . . . 18mytomorrows (nL) . . . . . . . . . . . . . . . . . . . . . . . 20nanoReproaG (GER) . . . . . . . . . . . . . . . . . . . . . 47

nestle S.a. (CH) . . . . . . . . . . . . . . . . . . . . . . . . . 45newron pharmaceuticals S.p.a. (IT) . . . . . . . . . . 46nexvet Biopharma (USa) . . . . . . . . . . . . . . . . . . 18nitin Lifesciences Ltd (Ind) . . . . . . . . . . . . . . . . 38nordic nanovector aS (n) . . . . . . . . . . . . . . . . . 18northwest E-Health (UK) . . . . . . . . . . . . . . . . . . 20novacyt Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 40novartis aG (CH) . . . . . . . . . . . . . . . . . . 22, 25, 44novo nordisk a/S (dK) . . . . . . . . . . . . . . . . . . . . 28novozymes a/S (dK) . . . . . . . . . . . . . . . . . . 29, 38octreopharm GmbH (GER) . . . . . . . . . . . . . . . . 44onTarget Chemistry (SE) . . . . . . . . . . . . . . . . . . . 38onxeo S.a. (dK) . . . . . . . . . . . . . . . . . . . . . . . . . 39opGen (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18opIS s.r.l. (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 23oSE pharma Sa (F) . . . . . . . . . . . . . . . . . . . . . . . 24oxford nanopore Technologies Ltd. (UK) . . . . . . 94perkinElmer (LaS) Germany GmbH . . . . 63, 66, 68Pfizer (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8pharmamar (ES) . . . . . . . . . . . . . . . . . . . . . . . . . 47philogen S.p.a. (IT) . . . . . . . . . . . . . . . . . . . . . . . 23poli Group Holding S.r.l. (nL) . . . . . . . . . . . . . . . 46polichem S.a. (CH) . . . . . . . . . . . . . . . . . . . . . . . 46polpharma biologics (pL) . . . . . . . . . . . . . . . 64, 65porta Systems aG (GER) . . . . . . . . . . . . . . . . . . . 18poxel Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18prasinotech Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . 38primer disign Ltd. (UK) . . . . . . . . . . . . . . . . . . . . 40proFibrix BV (nL) . . . . . . . . . . . . . . . . . . . . . . . . 28pronutria Biosciences (USa) . . . . . . . . . . . . . . . . 45prothena Corp. plc (IRL) . . . . . . . . . . . . . . . . . . . 24protix BV (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . 41Qiagen nV (GER) . . . . . . . . . . . . . . . . . . . . . 29, 71Qualcomm (USa) . . . . . . . . . . . . . . . . . . . . . . . . 20Recipharm aB (n). . . . . . . . . . . . . . . . . . . . . . . . 38Relief Therametrics Sa (CH) . . . . . . . . . . . . . . . . 18Riboxx GmbH (GER) . . . . . . . . . . . . . . . . . . . . . 41Rx Securities (UK) . . . . . . . . . . . . . . . . . . . . . . . . 29S.E.C.I. Spa (IT) . . . . . . . . . . . . . . . . . . . . . . . . . 47Sanofi SA (F) . . . . . . . . . . . . . . . . 8, 35, 36, 37, 44SaS – Scandinavian airlines (SE) . . . . . . . . . . . 39Scancell Holding plc. (UK) . . . . . . . . . . . . . . . . . 23Segetis (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . 46Sensorion aG (CH) . . . . . . . . . . . . . . . . . . . . . . . 18Seres Therapeutics (USa) . . . . . . . . . . . . . . . . . . 18Servier (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23Spark Therapeutics (USa) . . . . . . . . . . . . . . . . . . 18Stora Enso Ventures oy (FI) . . . . . . . . . . . . . . . . . 39Surface oncology (USa) . . . . . . . . . . . . . . . . . . . 44Swiss Biotech association (CH) . . Supplement, Cp3Syngenta aG (CH) . . . . . . . . . . . . . . . . . . . . . . . 45Taconic Biosciences (USa) . . . . . . . . . . . . . . . .Cp2Takeda pharmaceuticals (Jp) . . . . . . . . . . . . . 22, 37Taurus pharma GmbH (GER) . . . . . . . . . . . . . . . 46Therametrics Holding aG (CH) . . . . . . . . . . . . . . 18Theravectys (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 28ThermiGen LLC. (USa) . . . . . . . . . . . . . . . . . . . . 46ThermoFisher Scientific (USA) . . . . . . . . . . . . . . 71Threshold pharmaceuticals Inc. . . . . . . . . . . . . . 25Tollys SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . 41Transgene Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . 40Vectura Group plc (UK) . . . . . . . . . . . . . . . . . . . 29Vernalis (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Vetter pharma-Fertigung GmbH & Co.KG (GER) . 25Viomedo (GER) . . . . . . . . . . . . . . . . . . . . . . . . . . 20Vossius & partner (GER) . . . . . . . . . . . . . . . . . . . 20Woodford Investment management LLp (UK) . . . 40ZaB Brandenburg Ec. dev. Board (GER) . . . . . . . 11Zosano pharma (USa) . . . . . . . . . . . . . . . . . . . . 18

FREE EXCERPT

SWISS BIOTECH DAY 2016The leading Life Sciences Conference in Switzerland andAnnual General Assembly of the Swiss Biotech Association

12 APRIL 2016 Basel Congress Center

The Swiss Biotech Day is the leading biotechnology conference in Swit-zerland. Constantly growing, the 2016 event will bring together around 500 senior executives from the life science industry across Europe.

Programme highlights will be keynotes given by senior representatives of Siegfried AG and Bayer Pharma AG, as well as the presentation of the 2016 Swiss Biotech Report. Parallel sessions in the afternoon will focus on emer-ging biotechnology companies, publicly listed biotech companies, geogra-phic hotspots in biotech and compliance. Additionally, there will be an exhi-bition and extensive partnering opportunities with one-to-one meetings.

More information on the conference and online registration can be found at: www.swissbiotechday.ch

Foto

: Leo

nid

And

rono

v/Fo

tolia

.com

Media Partner:

Sponsors:

Organised by:

@

“WHITE BIOTECHNOLOGY” WORKING GROUP

Leading chemical companies are exploring the op-portunities that have been opened up by modern bio-technology, especially in the field of “white” or indus-trial biotechnology. And they are also applying thesetechnologies, wherever it makes sense. The SBA takessuch initiatives seriously and has formed a workinggroup specifically dedicated to white biotechnology.The Swiss Industrial Biocatalysis Consortium is animportant partner in this effort. The group includesleading multinational companies that support whitebiotechnology as a pillar of economic growth. Theplanned activities are in agreement with OECD strategies.In partnership with the Swiss Biotechnet (see pages14/15) the SBA develops training programmes and use-ful support tools for the industry. It is of importancethat the industry specifies its training needs so thatthe academic side can create tailor-made education.This strategy ensures that the industry gets the rightworkforce with the right education. The SBA profitsfrom the marketing alliance “Swiss Biotech” (see box)in a multiplied form. Thanks to Swiss Biotech, the

sector is internationally visible. The project-specificparticipating companies (most of them young and in-ternationally less savvy) find a comprehensive partnerwhich is helping to put them in the public window.The participating Life Science Regions are importantinternal carriers of the dynamics in the Biotech sec-tor, thus enhancing the common understanding of theindustry. This and more knowledge is brought intoEuropa Bio, the European Biotech Association, wherethe SBA is an active member.

22

SWISS BIOTECH...

...is an alliance of four leading Biotech regions ofSwitzerland (Bio Alps, BioPolo Ticino, Basel Areaand Greater Zurich Area). They have combined ef-forts to streamline interests of the national biotechsector. The SWX Swiss Exchange holds a leadingposition in terms of lifescience listings and offerscompanies from that industry – be they located inSwitzerland or abroad – access to an international-ly recognised financial marketplace. The initiativewas co-founded by the SBA which also managesthe executive office of Swiss Biotech.

Domenico Alexakis is Executive Director of the Swiss Biotech Association.

...ONE BIOTECH CLUSTER

For further information please visit www.swissbiotechassociation.ch

www.swissbiotech.org

In cooperation with: Supporting partner:

Your premier opportunity to learn from and collaborate with thought leaders across key health care product development stakeholder groups.

Exhibiting Opportunities Available:Join our New Global Village andinteract face-to-face with 2,500+participants, your future customers.

DIA 28th Annual EuroMeetingINnovation Do You Win by Being IN?

6-8 April 2016 | CCH | Hamburg, Germany

Visit DIAglobal.org/EM2016 today to learn more register